All In Biotech

Drug Trial Radar · NCT04120246

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 8, 2020

Primary completion

Feb 1, 2028

Study completion Feb 1, 2030

Sponsor

Lead sponsor
Veana TherapeuticsIndustry
Sponsor type
Industry
Collaborators
University of Washington
First posted
Oct 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpha-TEA may also alter cancer growth by stimulating the body's immune response against the tumor. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of HER2+ refractory and metastatic breast cancer compared to usual treatment.

Conditions

  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2 Positive Breast Carcinoma
  • Metastatic Breast Carcinoma
  • Refractory Breast Carcinoma

Interventions

  • Alpha-tocopheryloxyacetic AcidDrug

    Given PO

  • TrastuzumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events of 4 escalating doses of alpha-tocopheryloxyacetic acid (TEA) therapy when combined with trastuzumabTime frame: Up to 4 years
  2. Clinical response rate of alpha-TEA when combined with trastuzumabTime frame: Up to 4 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Institute - Franz Clinic

    Portland, Oregon

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.